## Linifanib

# Inhibitor effective against all VEGF and PDGF receptors

Linifanib is an orally active multi-targeted receptor tyrosine kinase inhibitor for the treatment of various cancers. The compound is designed to inhibit vascular endothelial growth factor and platelet-derived growth factor receptors and is a multitargeted tyrosine kinase receptor inhibitor that suppresses FLT3 signaling. It is in phase III development for liver cancer and phase II development for non-small cell lung cancer, breast cancer, and colorectal cancer in the US, the EU and other areas of the world. Recent research also indicates that Linifanib inhibits proliferation and induces apoptosis in Aml) patient cells via reduction of AKT and GSK3 $\beta$  phosphorylation and maybe influential in Aml therapy.


### **Ordering Information**

Order Online »

**ENZ-CHM168-0005** 5mg

Manuals, SDS & CofA

**View Online** »



#### **Handling & Storage**

**Use/Stability** As indicated on product label or CoA when stored as recommended.

Short Term Storage +4°C

Long Term Storage -20°C

**Shipping** Ambient Temperature

#### Regulatory Status RUO - Research Use Only

#### **Product Details**

**Alternative Name** A-741439, ABT-869, RG3635, N-□[4-□(3-□amino-□1H-□ndazol-

 $\Box$ 4- $\Box$ yl)phenyl]- $\Box$ N'- $\Box$ (2- $\Box$ fluoro- $\Box$ 5- $\Box$ methylphenyl)- $\Box$ urea

**Appearance** Brown powder.

**CAS** 796967-16-3

Couple Target PDGF receptor, VEGFR

Couple Type Inhibitor

Formula  $C_{21}H_{18}FN_5O$ 

**Identity** Determined by EM-MS, NMR

MW 375.4

Purity ≥98% (HPLC)

**Soluble** in DMSO (75mg/ml) or ethanol (5mg/ml).

Last modified: May 29, 2024



European Sales Office